CAD106

INTRODUCTION This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity… (More)

CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106… (More)

Active or passive immunotherapy is expected to slow or stop the pathological process of Alzheimer's disease (AD). Immunotherapy… (More)

PURPOSE OF REVIEW We reviewed clinical trials on active and passive anti-β-amyloid (Aβ) immunotherapy for the treatment of… (More)

Dementia is a public health priority and one of the major contributors to morbidity and global non-communicable disease burden… (More)

BACKGROUND Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer's… (More)

A previous phase II trial of another Aβ-targeted immunotherapy, AN1792, was suspended early as the treatment caused… (More)

As a neurodegenerative disorder, Alzheimer disease (AD) is the most common form of dementia found in the aging population… (More)

Immunization against amyloid-β (Aβ) can reduce amyloid accumulation in vivo and is considered a potential therapeutic approach… (More)

Vaccines targeting the amyloid-β (Aβ) peptide have promise as immunotherapies for the treatment of Alzheimer disease (AD). Human… (More)